NCT03190915 2026-03-19
Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
23 trialsNCT01089101 2026-03-18
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT03871257 2026-03-18
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT05388370 2026-03-12
PASS of Paediatric Patients Initiating Selumetinib
AstraZeneca
Active not recruiting
NCT00924196 2026-03-09
Natural History Study of Patients With Neurofibromatosis Type I
National Institutes of Health Clinical Center (CC)
Active not recruiting
NCT02407405 2026-03-05
MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT01362803 2026-03-02
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting
NCT05101148 2026-02-23
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
AstraZeneca
Phase 1 Active not recruiting
NCT03975829 2026-02-13
Pediatric Long-Term Follow-up and Rollover Study
Novartis
Phase 4 Active not recruiting
NCT04590235 2026-01-30
A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
AstraZeneca
Phase 1 Active not recruiting
NCT05363267 2026-01-13
NF-1, Nutraceutical Intervention
Masonic Cancer Center, University of Minnesota
Phase 1 Active not recruiting
NCT04924608 2026-01-12
KOMET
AstraZeneca
Phase 3 Active not recruiting
NCT05677594 2026-01-12
Multi-parametric Biomarker Development to Predict Malignant Conversion in Patients With Neurofibromatosis Type 1
Johns Hopkins University
Active not recruiting
NCT05309668 2025-12-18
SPRINKLE
AstraZeneca
Phase 1/2 Active not recruiting
NCT05581511 2025-10-14
cNF Natural Hx
Johns Hopkins University
Active not recruiting
NCT03962543 2025-08-07
ReNeu
SpringWorks Therapeutics, Inc.
Phase 2 Active not recruiting
NCT02964884 2025-06-24
Interventions for Reading Disabilities in NF1
Vanderbilt University
Phase 2 Active not recruiting
NCT05913037 2025-03-06
FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 3 Active not recruiting
NCT04954001 2024-11-12
Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 1/2 Active not recruiting
NCT04481048 2024-10-09
DoDNAC
Children's Hospital Medical Center, Cincinnati
Phase 2 Active not recruiting
NCT03741101 2024-04-11
plexifpc
Region Skane
Phase 2 Active not recruiting
NCT03363217 2023-11-27
Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.
St. Justine's Hospital
Phase 2 Active not recruiting
NCT03820778 2021-03-02
Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1
Children's National Research Institute
Phase NA Active not recruiting